Kanchan Healthcare Inc. has achieved FDA approval for its ANDA-217782, launching the generic version of oxcarbazepine oral tablets. The move positions the manufacturer to capture market share within a widely used anticonvulsant class as higher-priced branded alternatives face increasing pressure from biosimilars.